Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno C Medeiros

Showing results (41-50 of 109) with videos related to

Pageof 11
Sort By:
Journal of Oncology Practice|August 15, 2013
Qualitative analysis of practicing oncologists' attitudes and experiences regarding collection of patient-reported outcomesReshma Jagsi, Anne Chiang, Blase N Polite, et al.
Leukemia & Lymphoma|May 18, 2022
Factors associated with risk and prognosis of intensive care unit admission in patients with acute leukemia: a Danish nationwide cohort studyCecilie Velsoe Maeng, Christian Fynbo Christiansen, Kathleen Dori Liu, et al.
Advances in Therapy|June 22, 2019
Economic and Clinical Burden of Relapsed and/or Refractory Active Treatment Episodes in Patients with Acute Myeloid Leukemia (AML) in the USA: A Retrospective Analysis of a Commercial Payer DatabaseBhavik J Pandya, Chi-Chang Chen, Bruno C Medeiros, et al.
Blood Advances|March 10, 2020
Single-cell mutational profiling enhances the clinical evaluation of AML MRDAsiri Ediriwickrema, Alexey Aleshin, Johannes G Reiter, et al.
British Journal of Haematology|April 5, 2016
A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myelomaTamara J Dunn, Shira Dinner, Elizabeth Price, et al.
Journal of Managed Care & Specialty Pharmacy|April 14, 2020
Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer DatabaseBhavik J Pandya, Chi-Chang Chen, Bruno C Medeiros, et al.
International Journal of Hematology|May 27, 2018
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myelomaShira Dinner, Tamara J Dunn, Elizabeth Price, et al.
Haematologica|October 22, 2013
Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II studyRoland B Walter, Bruno C Medeiros, Kelda M Gardner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2017
Effects of Education and Income on Treatment and Outcome in Patients With Acute Myeloid Leukemia in a Tax-Supported Health Care System: A National Population-Based Cohort StudyLene Sofie Granfeldt Østgård, Mette Nørgaard, Bruno C Medeiros, et al.
Frontiers in Oncology|May 19, 2023
CD25 targeting with the afucosylated human IgG1 antibody RG6292 eliminates regulatory T cells and CD25+ blasts in acute myeloid leukemiaLaurène Pousse, Koorosh Korfi, Bruno C Medeiros, et al.
Pageof 11

Showing results (41-50 of 109) with videos related to

Sort By:
Pageof 11
Journal of Oncology Practice|August 15, 2013
Qualitative analysis of practicing oncologists' attitudes and experiences regarding collection of patient-reported outcomesReshma Jagsi, Anne Chiang, Blase N Polite, et al.
Leukemia & Lymphoma|May 18, 2022
Factors associated with risk and prognosis of intensive care unit admission in patients with acute leukemia: a Danish nationwide cohort studyCecilie Velsoe Maeng, Christian Fynbo Christiansen, Kathleen Dori Liu, et al.
Advances in Therapy|June 22, 2019
Economic and Clinical Burden of Relapsed and/or Refractory Active Treatment Episodes in Patients with Acute Myeloid Leukemia (AML) in the USA: A Retrospective Analysis of a Commercial Payer DatabaseBhavik J Pandya, Chi-Chang Chen, Bruno C Medeiros, et al.
Blood Advances|March 10, 2020
Single-cell mutational profiling enhances the clinical evaluation of AML MRDAsiri Ediriwickrema, Alexey Aleshin, Johannes G Reiter, et al.
British Journal of Haematology|April 5, 2016
A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myelomaTamara J Dunn, Shira Dinner, Elizabeth Price, et al.
Journal of Managed Care & Specialty Pharmacy|April 14, 2020
Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer DatabaseBhavik J Pandya, Chi-Chang Chen, Bruno C Medeiros, et al.
International Journal of Hematology|May 27, 2018
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myelomaShira Dinner, Tamara J Dunn, Elizabeth Price, et al.
Haematologica|October 22, 2013
Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II studyRoland B Walter, Bruno C Medeiros, Kelda M Gardner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2017
Effects of Education and Income on Treatment and Outcome in Patients With Acute Myeloid Leukemia in a Tax-Supported Health Care System: A National Population-Based Cohort StudyLene Sofie Granfeldt Østgård, Mette Nørgaard, Bruno C Medeiros, et al.
Frontiers in Oncology|May 19, 2023
CD25 targeting with the afucosylated human IgG1 antibody RG6292 eliminates regulatory T cells and CD25+ blasts in acute myeloid leukemiaLaurène Pousse, Koorosh Korfi, Bruno C Medeiros, et al.
Pageof 11